Company News
Intellia Phase 3 Therapy Cuts Attacks 89%
Phase 3 HAELO trial showed lonvo‑z reduced monthly attack rate by 89% versus placebo, from 1.79 to 0.19 attacks.
Moderate‑to‑severe attacks fell 91% in the treatment arm, with mean monthly rate 0.11 v
